What can I do to help a 66‑year‑old female diagnosed with mild neurocognitive disorder (possible early Alzheimer disease) while she undergoes magnetic resonance imaging (MRI) and biomarker testing?

What You Can Do to Help Her

While awaiting MRI and biomarker results, focus on implementing multi-domain lifestyle interventions immediately—including structured cognitive training, regular aerobic exercise (150 minutes weekly), optimizing cardiovascular risk factors, correcting sensory deficits, and establishing social engagement—as these modifiable interventions can slow cognitive decline even before definitive diagnosis 1, 2, 3.

Immediate Actions During Diagnostic Workup

1. Lifestyle Interventions (Start Now)

Physical Activity

• Implement regular aerobic exercise: 150 minutes per week of moderate-intensity activity
• This is the single most evidence-based non-pharmacologic intervention for slowing cognitive decline
• Exercise improves cerebral blood flow and may reduce neurodegeneration 2, 3

Cognitive Stimulation

• Engage her in structured cognitive training programs
• Activities should challenge multiple cognitive domains: memory, executive function, language
• Consider formal cognitive rehabilitation programs if available 4

Social Engagement

• Maintain and expand social connections
• Isolation accelerates cognitive decline; regular social interaction is protective 2, 4

2. Optimize Cardiovascular and Metabolic Health

Critical Risk Factor Management

• Aggressively control vascular risk factors: hypertension, diabetes, hyperlipidemia
• These are modifiable factors that significantly impact progression from MCI to dementia 2, 5, 4
• Review all medications for anticholinergic burden—discontinue or substitute drugs with anticholinergic effects that worsen cognition 2

Specific Targets:

• Blood pressure control (avoid hypotension which can worsen cognition)
• Glycemic control if diabetic
• Lipid management per cardiovascular guidelines

3. Sensory Function Correction

Hearing and Vision

• Complete the recommended annual hearing/vision evaluations promptly
• Correct any deficits immediately with hearing aids or glasses
• Sensory impairment independently accelerates cognitive decline and is highly modifiable 2

4. Screen and Treat Neuropsychiatric Symptoms

Depression and Anxiety

• 35-85% of MCI patients have neuropsychiatric symptoms, most commonly depression, anxiety, apathy, irritability 3
• These symptoms may predict faster progression and require treatment
• Depression in older adults can both mimic and coexist with MCI 6

Sleep Disorders

• Evaluate and treat sleep disturbances
• Poor sleep quality accelerates cognitive decline 2, 3

Preparing for Biomarker Results

Understanding the Diagnostic Process

What the Tests Mean:

• MRI: Will assess for hippocampal/entorhinal atrophy, vascular disease, and rule out other causes 3, 1
• Phosphorylated tau and amyloid ratio: High likelihood of AD if both amyloid (low Aβ42) and tau (elevated p-tau) are abnormal 3, 1, 7
• APOE testing: ε4 alleles increase risk of progression to dementia but don't determine diagnosis 8

Biomarker Interpretation 1, 7:

• High likelihood AD: Both amyloid and tau biomarkers positive
• Intermediate likelihood: One positive, one negative, or one untested
• Low likelihood AD: Both negative (suggests alternative cause)

Pre-Disclosure Counseling Considerations

Before receiving results, discuss 9:

• What positive biomarkers mean: increased risk of progression, not certainty
• Approximately 35% of MCI patients progress to AD dementia within 3 years (5-10% annually) 7
• Even with positive biomarkers, some individuals never convert to dementia during their lifetime 3
• Treatment implications if biomarkers confirm AD pathology

Medication Considerations

Current Evidence on Pharmacotherapy

Cholinesterase Inhibitors for MCI:

• Current guidelines recommend AGAINST cholinesterase inhibitors specifically for MCI 2
• Evidence is insufficient to support their use in the MCI stage
• However, if she progresses to mild AD dementia, these become appropriate 2

If Biomarkers Confirm AD Pathology:

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) become options once dementia criteria are met
• Rivastigmine may offer additional benefit in patients with vascular risk factors 5
• Memantine is reserved for moderate-to-severe stages 2

Emerging Treatments:

• Anti-amyloid antibodies (lecanemab, donanemab) require biomarker confirmation of amyloid pathology and are indicated for MCI or mild dementia due to AD 10
• These require specialized referral and monitoring

Monitoring and Follow-Up

Establish Baseline and Track Progression

Longitudinal Assessment 8:

• Document current cognitive performance across all domains
• Repeat cognitive testing every 6-12 months
• Progressive decline over time strengthens diagnostic accuracy
• Track functional abilities—preservation of independence distinguishes MCI from dementia 1, 6

Red Flags for Rapid Decline 5:

• MMSE <20 at baseline
• Early hallucinations or psychosis
• Extrapyramidal symptoms
• Multiple vascular risk factors
• These predict faster progression and require more frequent monitoring

Functional Monitoring

Activities of Daily Living:

• Basic ADLs (bathing, dressing, toileting): Should remain intact in MCI
• Instrumental ADLs (finances, medications, cooking): May show subtle difficulties 3, 11
• Significant IADL impairment suggests progression toward dementia

Caregiver Support and Planning

Immediate Caregiver Needs

Education and Resources:

• Connect with Alzheimer's Association or local memory disorder clinics
• Provide education about MCI, expected trajectory, and warning signs of progression
• Discuss advance care planning while she has capacity 7, 9

Anticipate Increased Burden:

• Even in MCI, caregivers experience burden
• Establish support systems now before potential progression
• Consider support groups for caregivers of individuals with cognitive impairment

Legal and Financial Planning

While Capacity Exists:

• Complete advance directives
• Establish durable power of attorney for healthcare and finances
• Discuss driving safety and future planning
• These conversations are easier before significant progression 9

Common Pitfalls to Avoid

1. Waiting for biomarker results to start interventions: Begin lifestyle modifications immediately—they're beneficial regardless of etiology
2. Ignoring vascular risk factors: These are highly modifiable and significantly impact progression
3. Overlooking sensory deficits: Hearing and vision correction is simple but often neglected
4. Missing depression: Can coexist with and worsen cognitive symptoms
5. Premature medication: Cholinesterase inhibitors are not indicated for MCI per current guidelines 2
6. Inadequate follow-up planning: Establish regular monitoring schedule now

After Biomarker Results Return

If Biomarkers Confirm AD Pathology

• Discuss prognosis: increased risk of progression but variable timeline
• Consider enrollment in clinical trials or access to anti-amyloid therapies if appropriate
• Intensify lifestyle interventions and risk factor management
• Plan for more frequent cognitive monitoring (every 6 months)

If Biomarkers Are Negative or Mixed

• Explore alternative etiologies: vascular, psychiatric, medication effects, other neurodegenerative conditions 8
• Continue lifestyle interventions as they benefit cognitive health regardless of cause
• May require additional testing or specialist evaluation

Memory Clinic Follow-Up

The planned memory clinic referral is appropriate and should include 1:

• Comprehensive neuropsychological testing
• Review of all biomarker results in clinical context
• Formulation of individualized management plan
• Discussion of prognosis and treatment options
• Caregiver education and support resources